Psoriasis (PsO) is a chronic, immune-mediated inflammatory skin disease that affects approximately 2–3% of the population. Among patients with PsO, an estimated 40–50% have psoriatic nail disease, which is associated with and directly contributes to a greater clinical burden and worse quality of life in these patients. In this review, we examine how recent advances in the use of new diagnostic techniques have led to improved understanding of the link between nail and musculoskeletal manifestations of psoriatic disease (PsD; e.g., enthesitis, arthritis) and we review targeted therapies for nail PsO (NP).

Methods. We performed a literature search to identify which systemic therapies approved for the treatment of PsO and/or psoriatic arthritis (PsA) have been evaluated for the treatment of NP, either as a primary or secondary outcome. A total of 1546 articles were identified on February 18, 2019, and evaluated for relevance.

Results. We included findings from 66 articles on systemic therapies for the treatment of NP in PsD. With several scoring systems available for the evaluation of psoriatic nail disease, including varied subtypes and application of the Nail Psoriasis Area Severity Index, there was a high level of methodological heterogeneity across studies.

Conclusion. NP is an important predictor of enthesitis, which is associated with the early stages of PsA; therefore, it is important for rheumatologists and dermatologists to accurately diagnose and treat NP to prevent nail damage and potentially delay the onset and progression of joint disease. Further research is needed to address the lack of both standardized NP scoring systems and well-defined treatment guidelines to improve management of PsD.

Key Indexing Terms: psoriasis, psoriatic arthritis, spondyloarthropathy

Figure 2. Examples of (A) nail matrix and (B) nail bed psoriasis. Images courtesy of Phoebe Rich, MD.
among rheumatologists, primary care providers, and dermatologists to improve identification and management of PsA.

Our review (1) provides an overview of NP, (2) discusses the use of new diagnostic techniques with a focus on the resulting improved understanding of the link between nail and musculoskeletal manifestations of psoriatic disease (PsD), and (3) reviews the current targeted therapies for NP. Literature search details are provided in the Supplementary Data (available with the online version of this article).

Overview of the nail unit
The nail unit is composed of 4 epithelial structures—the nail matrix, the nail bed, the hyponychium, and the proximal and lateral nail folds, which function to produce, attach, and protect the nail plate (Figure 1).5,13 The nail matrix cells differentiate into the hard, rectangular, translucent structure we refer to as the nail plate, which is nonliving tissue and hence, technically, not part of the nail unit. The hyponychium and the lateral and proximal nail folds act as seals to prevent environmental pathogens and irritants from penetrating the nail unit and causing disease.

The primary function of the nail is to protect the digits from injury, enhance fine motor function of the digits, and to scratch in defense or to quell itches. The healthy nail plate is translucent, hard, and colorless in all people and derives its apparent color from underlying structures. The white semicircular structure in the proximal nail, called the lunula, represents the distal portion of the nail matrix seen through the proximal nail plate. The highly vascularized nail bed results in the apparent pink color of the nail, while the white free edge of the nail plate is due to air underneath and explains the white color of the lifted nail plate in onycholysis.

The nail matrix produces the nail plate by differentiation of nail matrix keratinocytes into flattened onychocytes, without the formation of keratohyalin granules. Sheets of matrix squamous cells flatten and are closely packed in lamella of the nail plate. Sulfurous proteins and calcium phosphate provide strength and flexibility to nail plate keratin. The rate of nail plate growth limits the time scale over which changes can be observed. In healthy individuals, nail elongation speed (NES) is approximately 0.1 mm/day; in people with PsO, NES increases by around 10–25%.20,21

The nail bed firmly attaches to the ventral aspect of the nail plate by way of parallel longitudinal ridges and grooves that interlock with and bind the nail plate tightly to the nail bed as it grows distally. Nail bed epithelium does not produce keratohyalin granules and does not have a granular layer—unlike the nail folds and hyponychium, which exhibit the keratinization typical of normal volar skin. The nail bed also contains a rich vascular system within the parallel longitudinal grooves between the ridges, which explains the orientation of splinter hemorrhages within the nail bed.5,13

Because of the anatomy of the nail unit and its connection to the DIP joints, the presence of NP can serve as a predictor for development of PsA, especially of extensor tendon enthesopathy of the DIP joints.16,17,18,19 This association has been linked to the anatomical connection between the nail matrix and the entheses of the DIP joints (Figure 1). The nail is anchored to underlying bone by a “mini-enthesis network,” whereby the extensor tendon that crosses the DIP is fused with the nail matrix and nail root.15 This may explain why patients with PsA, who usually present with enthesitis of the DIP joint, also frequently (although not always) present with nail changes characteristic of NP.

Diagnosis and assessment of NP
Overview. NP can occur in all portions of the nail unit, and the clinical features of NP, such as pitting, onycholysis, and crumbling, depend on which part of the nail unit is affected by the psoriatic inflammatory process (Figure 2).10,12,13,22,23 The symptoms of nail matrix PsD depend on the precise location of PsD in the proximal or distal matrix, as well as the transverse extent and duration of the disease process. Pitting, crumbling, and leukonychia are caused by foci of PsO pathology in the nail matrix that forms the nail plate. Other less common nail matrix features include Beau lines (deep horizontal indentations), onychomadesis (separation of the nail plate from the nail matrix), trachyonychia (rough, ridged nails), and total nail plate dystrophy. PsO in the nail bed causes oil-drop (salmon patch) dyschromia, nail bed hyperkeratosis, and splinter hemorrhages—all of which disrupt nail plate attachment—and, eventually, onycholysis. PsO of the proximal and lateral nail folds resembles PsO on other skin sites. The cuticle attachment can be destroyed by PsO of the nail folds, which results in nail plate surface irregularities similar to those observed in paronychia.

Diagnosis. NP can usually be diagnosed based on clinical features in patients with accompanying skin and/or joint symptoms of PsD.23 In the absence of diagnosed skin or joint PsD, NP can be difficult to differentiate from other causes of nail dystrophy, and idiopathic nail dystrophy should be part of the differential diagnosis.13,23,24 The clinical presentation of NP can vary greatly based on the part of the nail unit that is affected (Figure 2). NP color changes, hyperkeratosis, onychorrhexis, and nail plate thickening often resemble onychomycosis, which is frequently observed in up to 60% of patients with PsO. Changes in the distal or marginal nail plate can resemble lichen planus.

Biopsies can provide information on histopathologic nail changes that can inform difficult diagnoses, but nail biopsies are rarely performed because they are invasive procedures associated with bleeding, pain, permanent scarring, nail dystrophy, and increased risk for secondary infection.24,25,26 Nail clippings can be analyzed to identify fungal infection, parakeratosis, and subungual hyperkeratosis.27,28

Imaging techniques, including high-resolution ultrasound, dermoscopy, videodermoscopy, optical coherence tomography, capillaroscopy, and confocal laser scanning microscopy, are increasingly being used as noninvasive diagnostic tools for identifying various features of NP and response to treatment.26,29,30,31,32,33 Once NP is diagnosed, it is important for clinicians to be able to assess its severity in order to determine an optimal treatment strategy and to monitor the response to therapy.24

Nail assessment and scoring systems
Overall clinical severity has been described using the fingernail physician global assessment (f-PGA),15,36,37 by which
the fingernails are assessed for nail plate pitting, crumbling, onycholysis, oil-drop discoloration, and/or nail bed hyperkeratosis on a 5-point scale, from 0 (clear) to 4 (severe), and by simple visual analog scale (VAS; used in some PsA trials). The need for more precise outcome measures to determine therapeutic efficacy in clinical trials has led to several more complex scoring systems (Table 1).

The Nail PsO Area Severity Index (NAPSI) is the most widely used tool for scoring NP in clinical trials. Using the NAPSI, each nail is divided into four quadrants and scored based on the presence or absence of psoriatic changes to the nail matrix and the nail bed (Figure 3). Scoring the NAPSI usually assesses fingernails, for a total score of 0–80, but some studies have also included the toenails (scoring 0–160; Table 2). The NAPSI is the only system that explicitly separates nail matrix and nail bed symptoms.

A modified version of the NAPSI (mNAPSI), used in several clinical trials to date, demonstrated superior interrater variability and correlations with patient and physician global assessments. Scoring of the mNAPSI is based on the whole of each fingernail, to avoid variability in defining quadrants. Four abnormalities are scored as 0 (absent) or 1 (present): leukonychia, splinter hemorrhages, hyperkeratosis, and red spots in the lunula. Three other abnormalities are scored between 0 and 3, depending on their extent: the percentage area of onycholysis (considered together, as they are part of the same pathological process) is scored as 0 (none), 1 (1–10%), 2 (11–30%), or 3 (> 30%); the number of pits is scored as 0 (none), 1 (1–10 pits), 2 (11–49 pits), or 3 (≥ 50 pits); and the percentage area of nail plate crumbling is scored as 0 (none), 1 (1–25%), 2 (26–50%), or 3 (> 50%). The total range of fingernail scores for mNAPSI is 0–130. By assessing the nail as a whole rather than by quadrant, the mNAPSI eliminates a source of variation, but this may reduce its sensitivity to early changes in response to treatment.

A common strategy to simplify follow-up assessments has been the use of a target nail, in which only the baseline worst affected nail is quantified at follow-up. In the original NAPSI paper, the authors suggested that a "target NAPSI" could be scored by the presence or absence of each of the 4 nail bed and 4 nail matrix anomalies in each quadrant of a single nail, for a score ranging from 0 to 32. A "modified target NAPSI" (not to be confused with mNAPSI) was subsequently proposed, in which each of the 8 nail anomalies in each quadrant were scored as 0 (none), 1 (mild), 2 (moderate), or 3 (severe), for a total score of 0–96. However, neither of these more complex target nail systems are commonly used—most studies reporting data on target nails have used the regular NAPSI or mNAPSI applied to a single nail, for a score of 0–8 or 0–13 (Table 2).

Five other nail scoring systems are used less frequently: (1) Psoriasis Nail Severity Score, (2) Baran system, (3) Cannavò system, (4) Nail Area Severity score, and (5) Nijmegen–Nail PsO Activity Index tool (N-NAIL), which combines the elements from other systems that best predicted clinical assessments (Table 1).

### Table 1. Comparison of nail scoring systems used in studies of currently approved treatments for PsO and/or PsA.

<table>
<thead>
<tr>
<th>Symptoms</th>
<th>NAPSI by Quadrant</th>
<th>Target NAPSI by Quadrant</th>
<th>mNAPSI by Quadrant</th>
<th>N-NAIL by Quadrant</th>
<th>f-PGA by Quadrant</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nail matrix symptoms</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beau lines</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Leukonychia</td>
<td>Absent = 0; 1 line = 1; 2 lines = 2; ≥ 3 lines = 3</td>
<td>Clear = 0; Minimal = 1; Mild = 2; Moderate = 3; Severe = 4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nail plate crumbling</td>
<td>Absent = 0; 1–25% = 1; 26–50% = 2; &gt; 50% = 3</td>
<td>Absent = 0; mild = 1; moderate = 2; severe = 3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pitting</td>
<td>Absent = 0; 1–10 pits = 1; 11–49 pits = 2; ≥ 50 pits = 3</td>
<td>Absent = 0; mild = 1; moderate = 2; severe = 3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Red spots in the lunula</td>
<td>Present = 1</td>
<td>Present = 1</td>
<td>Present = 1</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>Nail bed symptoms</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hyperkeratosis</td>
<td>Absent = 0; 1 mm = 1; 2 mm = 2; ≥ 3 mm = 3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oil drop or salmon patch</td>
<td>Absent = 0; 1–10% = 1; 11–30% = 2; &gt; 30% = 3</td>
<td>Absent = 0; 0–25% = 1; 25–50% = 2; &gt; 50% = 3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Onycholysis</td>
<td>Present = 1</td>
<td>Present = 1</td>
<td>Present = 1</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>Splinter hemorrhages</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Score range per nail (or “target” nail)</td>
<td>0–8</td>
<td>0–32</td>
<td>0–13</td>
<td>0–15</td>
<td>0–4</td>
</tr>
<tr>
<td>Total for fingernails</td>
<td>0–80</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Total for all nails</td>
<td>0–160</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

*Note that the mNAPSI is sometimes listed as 0–14 per nail, 0–140 total, due to a misprint in the original paper.* f-PGA: fingernail physician global assessment; mNAPSI: modified NAPSI; NAPSI: Nail Psoriasis Area Severity Index; N-NAIL: Nijmegen-Nail Psoriasis Activity Index Tool; PsA: psoriatic arthritis; PsO: psoriasis.
S coring systems that have been developed to measure the effect of NP on QOL include the 10-item Nail Psoriasis Quality of Life scale and the Nail Assessment in PsO and PsA; however, published data on the use of these tools are extremely limited.47,48,49

A lthough many nail scoring systems are available, most of these instruments were developed for use in clinical trials and are typically not used in daily practice. Rheumatologists and dermatologists will usually note the presence or absence of nail lesions but may not always use objective scoring methods to evaluate the severity of nail disease or response to treatment. It should also be noted that the reliability of NAPSI when used by nonexpert rheumatologists has been shown to be variable.50 Another option is the physician global VAS for NP, which can be performed quickly and easily by clinicians in a busy clinic, making it more likely to be used than a more time-consuming assessment tool such as NAPSI, mNAPSI, or N-NAIL. Although a physician VAS does not provide the same level of detail as other tools and does not differentiate between nail matrix and nail bed pathology, it correlates strongly with the


Figure 4. (A) Ultrasound imaging of the nail/enthesis complex in a 64-year-old woman with psoriasis, psoriatic arthritis, and nail disease. (B) Up arrow: extensor tendon fibers split and fuse with the periosteum over the terminal phalanx, which is connected to the nail bed, thus indirectly anchoring the enthesis to the bone of the phalanx. (C) Down arrow: extensor tendon fibers enveloping the nail root. DP: distal phalanx; MP: middle phalanx. Images courtesy of Catherine J. Bakewell, MD.
Table 2. Overview of dedicated, prospective NP studies of currently approved treatments for PsO and/or PsA.

<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>Study, Year</th>
<th>Patient Population</th>
<th>Nail PsO Outcome Measure(s)</th>
<th>Key Nail PsO Efficacy Results</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Nonbiologics</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acitretin (0.2–0.3 mg/kg QD for 6 months)</td>
<td>Tosti, 2009&lt;sup&gt;95&lt;/sup&gt;</td>
<td>M/S isolated fingernail PsO (n = 36)</td>
<td>Primary: NAPSI (0–80), target mNAPSI (0–13)</td>
<td>Change from BL to 6 months, mean %</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NAPSI</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Modified target NAPSI</td>
</tr>
<tr>
<td>CsA (3.5 mg/kg/d) ± topical calcipotriol BID</td>
<td>Feliciani, 2004&lt;sup&gt;92&lt;/sup&gt;</td>
<td>S PsO with nail PsO (n = 54)</td>
<td>Primary: 3-level improvement score (+, ++, ++++)</td>
<td>Patients with improved clinical appearance of nails, %</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CsA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CsA + topical</td>
</tr>
<tr>
<td>CsA (3 mg/kg BID)</td>
<td>Abe, 2011&lt;sup&gt;93&lt;/sup&gt;</td>
<td>Pretreated for nail PsO (n = 32)</td>
<td>Primary: “Nail PASI” (unclear)</td>
<td>Complete resolution in 25%; significant improvement in 50%</td>
</tr>
<tr>
<td>MTX (15 mg QW, initial dose) vs CsA (5 mg/kg QD)</td>
<td>Gümsel, 2011&lt;sup&gt;94&lt;/sup&gt;</td>
<td>PsO or PsA and nail PsO (n = 37)</td>
<td>Primary: NAPSI (0–80)</td>
<td>NAPSI change from BL to 24 weeks (mean %):</td>
</tr>
<tr>
<td>MTX (15–25 mg QW)</td>
<td>Krajewska-Włodarczyk, 2018&lt;sup&gt;67&lt;/sup&gt;</td>
<td>Nail PsO, DIP enthesitis, MTX-naive (n = 319 nails in 32 pts)</td>
<td>Primary: US imaging of nail plate, nail bed, and nail matrix</td>
<td>MTX (−43.3), CsA (−37.2)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Secondary: mNAPSI (0–130)</td>
<td>Thickness</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Nail plate</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PsO pts</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Nail bed</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PsO pts</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Nail matrix</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PsO pts</td>
</tr>
<tr>
<td>TRI acetonide injection (10 mg/mL) into nail bed/matrix (4 sites, repeated at 2 months if poor response)</td>
<td>Salem, 2008&lt;sup&gt;95&lt;/sup&gt;</td>
<td>Nail PsO (n = 35, 100 nails)</td>
<td>Primary: 0–3 severity score for various nail pathologies</td>
<td>Response at 6 months (no. nails)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Partial</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Complete</td>
</tr>
<tr>
<td>TRI acetonide (intramatricial needle-free injection)</td>
<td>Battista, 2014&lt;sup&gt;96&lt;/sup&gt;</td>
<td>Nail PsO (n = 17)</td>
<td>Primary: Target NAPSI (0–8)</td>
<td>Target NAPSI, mean</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>BL NAPSI</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Week 16 NAPSI</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Week 16 reduction from BL</td>
</tr>
<tr>
<td>TRI (intraleisional injection)</td>
<td>Boontaveeyuwat, 2019&lt;sup&gt;97&lt;/sup&gt;</td>
<td>Nail PsO (n = 48 nails)</td>
<td>Primary: Target NAPSI for each affected nail (0–32)</td>
<td>Temporary reduction in target NAPSI over 1–4 months</td>
</tr>
<tr>
<td>Intramatrical injection of: TRI acetonide (10 mg/mL) vs MTX (25 mg/mL) vs CsA (50 mg/mL)</td>
<td>Mittal, 2018&lt;sup&gt;97&lt;/sup&gt;</td>
<td>17 pts with 90 affected fingernails</td>
<td>Primary: NAPSI (0–80)</td>
<td>Week 24</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TRI</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>MTX</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CsA</td>
</tr>
</tbody>
</table>
### Table 2. Continued.

<table>
<thead>
<tr>
<th>Drug(s)</th>
<th>Study, Year</th>
<th>Patient Population</th>
<th>Nail PsO Outcome Measure(s)</th>
<th>Key Nail PsO Efficacy Results</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Biologics</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TNFi: ADA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ADA (80 mg at Week 0, then 40 mg Q2W)</td>
<td>Rigopoulos, 2010&lt;sup&gt;88&lt;/sup&gt;</td>
<td>S PsO (n = 7) or PsA (n = 14), with nail PsO</td>
<td>Primary: NAPSI fingers (0–80), NAPSI toes (0–80)</td>
<td>NAPSI, mean (SD)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PsO only</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Fingers</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>BL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>10.6 (1.2)</td>
</tr>
<tr>
<td>ADA (RWD)</td>
<td>Khoobzey, 2017&lt;sup&gt;99&lt;/sup&gt;</td>
<td>M/S PsO ± PsA and NAPSI ≥ 10 (n = 157)</td>
<td>Primary (RWD): NAPSI (0–160) 4 visits over ≤ 12 months</td>
<td>NAPSI change from BL, mean %</td>
</tr>
<tr>
<td>ADA (40 mg Q2W) vs PBO</td>
<td>Elekswi, 2018&lt;sup&gt;80&lt;/sup&gt;</td>
<td>M/S PsO plus ≥1 fingernail (n = 217)</td>
<td>Primary: mNAPSI (0–130), target mNAPSI (0–13), Secondary: NAPSI (0–80), nail PsO pain, NPPFS, B-SNIP50, f-PGA</td>
<td>mNAPSI&lt;sub&gt;75&lt;/sub&gt; Week 26</td>
</tr>
<tr>
<td>TNFi: ETN</td>
<td>Ortonne, 2013&lt;sup&gt;80&lt;/sup&gt;</td>
<td>M/S PsO, failed systemic for nail PsO (n = 69)</td>
<td>Primary: Target NAPSI (excluding thumb, 0–8), Secondary: NAPSI (excluding thumb, 0–64)</td>
<td>Target NAPSI change from BL, mean</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>QW</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Week 24</td>
</tr>
<tr>
<td>TNFi: IFX</td>
<td>Bianchi, 2005&lt;sup&gt;81&lt;/sup&gt;</td>
<td>Pre-treated PsO or PsA NAPSI &gt; 14 (n = 25)</td>
<td>Primary: NAPSI (0–80)</td>
<td>Week 14: 100% NAPI50</td>
</tr>
<tr>
<td></td>
<td>Rigopoulos, 2008&lt;sup&gt;82&lt;/sup&gt;</td>
<td>PsO/PsA with nail PsO starting IFX (n = 18)</td>
<td>Primary: NAPSI (0–80)</td>
<td>NAPSI, mean</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>BL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Week 14</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Week 38</td>
</tr>
<tr>
<td>IL-12/23 inhibitor: UST</td>
<td>Patsatsi, 2013&lt;sup&gt;83&lt;/sup&gt;</td>
<td>M/S PsO, nail PsO (n = 27)</td>
<td>Primary: NAPSI (0–160)</td>
<td>NAPSI, median (range)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>BL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Week 16</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Week 28</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Week 40</td>
</tr>
<tr>
<td>UST (45 mg at Weeks 0 and 4, then Q12W)</td>
<td>Rigopoulos, 2011&lt;sup&gt;84&lt;/sup&gt;</td>
<td>PsO with fingernail PsO (n = 27)</td>
<td>Primary: NAPSI (0–80)</td>
<td>NAPSI, mean (SD)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>BL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Week 16</td>
</tr>
<tr>
<td>Drug(s)</td>
<td>Study, Year</td>
<td>Patient Population</td>
<td>Nail PsO Outcome Measure(s)</td>
<td>Key Nail PsO Efficacy Results</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>------------------------------</td>
<td>-----------------------------</td>
<td>----------------------------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td>IL-17A inhibitors: SEC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SEC (300 mg or 150 mg Q4W)</td>
<td>Reich, 2018&lt;sup&gt;6&lt;/sup&gt;</td>
<td>M/S PsO, M/S nail PsO</td>
<td>Primary: NAPSI (0–80).</td>
<td>NAPSI change from BL, mean %</td>
</tr>
<tr>
<td></td>
<td>(NCT01807520; TRANSFIGURE)</td>
<td>(n = 198)</td>
<td>Secondary: target toenail</td>
<td>Finger nails</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>NAPSI (0–8), NAPPA</td>
<td>SEC</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>300 mg</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Week 16</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>−45.3</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>−37.9</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>−10.8</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>−15.3</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>−15.8</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>−9.7</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>−35.2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>−37.6</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>−</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>−</td>
</tr>
<tr>
<td>Head-to-head studies</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biologics</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ADA (80 mg at Week 0, 40 mg at Week 1, then Q2W) vs ETN (50 mg BIW for 12 weeks then 25 mg BIW for 12 weeks) vs IFX (infusion of 5 mg/kg at Weeks 0, 2, and 6, then Q8W)</td>
<td>Saraceno, 2013&lt;sup&gt;3&lt;/sup&gt;</td>
<td>Nail PsO (n = 60)</td>
<td>Primary: NAPSI (0–80)</td>
<td>NAPSI mean (SD)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ADA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ETN</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>IFX</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>BL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>33.1 (14.9)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>34.8 (12.4)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>33.3 (9.8)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Week 14</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>21.0 (8.9)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>23.6 (10.4)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>14.9 (4.2)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Week 24</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>11.4 (4.6)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>10.6 (5.3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3.1 (3.3)</td>
</tr>
</tbody>
</table>

ADA: adalimumab; BL: baseline; B-SNIPI50: 50% improvement in Brigham Scalp Nail Inverse Palmoplantar Psoriasis Composite Index; BW: bodyweight; CsA: cyclosporine A; DIP: distal interphalangeal; ETN: etanercept; f-PGA: fingernail physician global assessment; IFX: infliximab; IL: interleukin; IV: intravenous; MTX: methotrexate; mNAPSI: modified NAPSI; M/S: moderate to severe; NAPPA: Nail Assessment in Psoriasis and Psoriatic Arthritis; NAPSI: Nail Psoriasis Severity Index; NAPSI50/75/100: 50/75/100% reduction from BL in NAPSI; N-NAIL: Nijmegen–Nail Psoriasis Activity Index Tool; NPPFS: Nail Psoriasis Physical Functioning Severity; PASI: Psoriasis Area and Severity Index; PBO: placebo; PsA: psoriatic arthritis; PsO: psoriasis; pts: patients; RWD: real-world data; S: severe; SEC: secukinumab; TNFi: tumor necrosis factor inhibitor; TRI: triamcinolone; US: ultrasound; UST: ustekinumab.
mNAPSI and has excellent internal consistency and interrater reliability. Currently, there is a lack of consensus on the best NP scoring system, and most available instruments have not been completely validated or do not consider patient-specific factors such as overall burden or effect on QOL.

In addition to measures evaluated by physicians, patient global assessments are routinely used in studies of psoriatic conditions, generally based on a VAS. Because skin and joint symptoms are not always of the same severity, it was suggested that patients with PsA be given separate joint- and skin-focused VAS. Other clinicians subsequently suggested that nail symptoms should also be assessed by a separate VAS and showed that patient global nail VAS scores were moderately correlated to mNAPSI ($\rho = 0.55$).

**Nail manifestations as indicators of PsA and the importance of imaging**

Early, targeted treatment of NP is important because of the strong association between NP and the development of PsA. Patients with NP have an almost 3-fold higher risk of developing PsA than patients with PsO who do not have signs of nail dystrophy. Enthesitis is typically one of the earliest inflammatory changes observed in PsA, especially in the DIP joints. Development of NP may be the first sign of joint disease resulting from subclinical enthesitis in the closely anatomically associated entheses of the DIP extensor tendons (Figure 1 and Figure 4). This hypothesis is supported by results from several recent imaging studies showing that changes in the DIP joint capsule are closely linked to histologic nail changes and diffuse inflammatory responses extending from the enthesis to the nail. Nail measures were a primary study outcome in 22 of the included articles, a secondary outcome in 25 analyses (Supplementary Table 1, available with the online version of this article), incorporated imaging as a diagnostic or outcome measure, expanded use of imaging should be considered in future research.

**Recent developments in the treatment of NP**

**Overview of available therapies.** In recent years, substantial progress has been made in understanding the pathogenesis of psoriatic skin and joint disease, and several highly effective therapies are now available for the treatment of moderate to severe disease. However, NP research has been far more limited, and determining an appropriate treatment course can be challenging. This leads to the undertreatment of NP, which is a significant unmet need in the management of PsD in a Dutch Psoriasis Association survey, only 16% of patients were receiving treatment for NP.

Topical therapies are often used as first-line treatment for mild NP, but efficacy is modest even when disease is limited to minimal dystrophy in 1 or 2 nails. Application of topical therapies to nails is messy, most drugs do not adequately penetrate the nail bed and nail matrix, and use of topical corticosteroids can result in nail and underlying phalanx atrophy, nail striae, telangiectasias, tachyphylaxis, and other adverse consequences associated with systemic absorption of corticosteroids.

Available data, generally from cohort studies (Table 2), indicate that intraleSIONal injection of corticosteroids or methotrexate (MTX) directly into the nail matrix can be an effective treatment for NP; however, these procedures are unpopular among patients and physicians because they can be very painful and time consuming, with side effects including subungual hematomas, short-term paresthesia, and atrophy at the injection site.

The traditional oral systemic therapies—cyclosporine, MTX, acitretin, and leflunomide—generally provide modest efficacy, though many physicians consider these agents to be inadequate or inappropriate for the treatment of NP in the absence of significant skin disease.

There are now several classes of biologic and small-molecule therapies approved for the treatment of moderate to severe plaque PsO and/or PsA, including targeted inhibitors of tumor necrosis factor (TNF), interleukin (IL)-12/23, IL-17A, IL-23, phosphodiesterase 4, and Janus kinases. These agents have all demonstrated significant efficacy in psoriatic skin and/or joint disease, but because they are not specifically indicated for the treatment of NP, physicians can face insurance reimbursement challenges in patients with moderate to severe nail disease with minimal or no skin or joint involvement.

**Clinical trials evaluating efficacy in NP**

The 1546 articles identified by the literature search for approved systemic drugs included 66 clinical studies that reported outcomes for NP. Nail measures were a primary study outcome in 22 of the included articles, a secondary outcome in 25 articles, and a retrospective or posthoc outcome in the remaining 19. Half of the articles reported data for various patient subgroups, including one with nail symptoms at baseline, and half were analyses that reported data only for patients with nail symptoms. Nineteen articles reported prospective studies dedicated to NP (Table 2), and the remainder were subgroup analyses (Supplementary Table 1, available with the online version of this article). Moderate or severe PsO ± PsA was a clinical trial inclusion criterion in 33 articles, active PsA an inclusion criterion in 9 articles, and PsO and/or PsA in 6.
Twenty-two of the included articles reported placebo-controlled trials, including 5 articles reporting trials that also included an active comparator (UNCOVER-3,68,69 VOYAGE 1 and 2;35,37 and LIBERATE70), and 5 articles reported head-to-head trials with no placebo arm. Sixty-one articles reported trials focused on single agents, including nonbiologics; TNF, IL-12/23, IL-17A, and IL-23 inhibitors; and targeted synthetic disease-modifying antirheumatic drugs.

Perhaps the most notable observation about these studies (Table 2; Supplementary Table 1, available with the online version of this article) is the high level of heterogeneity, highlighting the need for a common clinical measure to allow for comparisons across studies. Although many studies used variations of the NAPSI, this index is not standardized and is heterogeneous in its subtypes and application.71 Some studies have reported raw scores, some have reported percentage reductions from baseline, and others have reported the proportion of patients meeting percentage reduction thresholds (e.g., NAPSI50) modeled on commonly used Psoriasis Area and Severity Index (PASI) targets, such as PASI75 and PASI100 (Table 2). It is important to note that the relatively slow growth of nails vs skin means that results can take longer to manifest, particularly for toenails, which means that trials may need to have longer follow-up to adequately assess nail outcomes.

The reports for nonbiological treatments had the greatest diversity in nail scoring methods. In the studies where NAPSI was reported, nonbiologics improved NAPSI by 40–50% after 4–6 months. In general, the biologic therapies were reported to achieve these levels of NAPSI improvement more rapidly, as early as Week 12. Most studies of biologics showed that NAPSI continued to improve, with NAPSI improvements rising to the 70–90% range for some drug types. Given the broad range of therapies used to treat NP, results from active-comparator studies may help inform treatment decisions. Real-world prospective studies have shown that biologic therapies are generally significantly more effective than conventional therapies.72 Comparative studies of different TNF inhibitors have shown that infliximab (IFX) provides greater improvement in NP than etanercept (ETN) or adalimumab (ADA); however, treatment with IFX is associated with higher risk of secondary fungal infection in patients with nail scrapings negative for fungus at baseline.73,74 Several comparisons between different classes of biologic agents have been undertaken. Treatment with the IL-17A inhibitor ixekizumab provided greater improvement in NP than treatment with the TNF inhibitor ETN over 12 weeks in the UNCOVER-3 study.68,69 Data from the VOYAGE 17 and VOYAGE 28 trials showed that nail improvements with the IL-23 inhibitor guselkumab were comparable to those observed with ADA through 24 weeks of treatment, but f-PGA responses were superior at Week 48. These results suggest that targeting the IL-17–IL-23 pathway may be a more effective long-term NP treatment strategy than blocking TNF. The importance of the IL-17 axis was highlighted in the TRANSFIGURE trial9 (NCT01807520), a placebo-controlled study evaluating secukinumab (SEC) specifically in patients with NP, SEC led to NAPSI reductions at 16 and 32 weeks that were superior to placebo and similar to, or numerically greater than, those with other biologics at similar time points.

Accurate comparisons of data between studies are made difficult by the heterogeneity of patient populations in subanalyses investigating NP, the fact that less than one-third of articles reported placebo-controlled trials, and the differing nail outcome measures used. This suggests a need for further placebo-controlled, randomized trials focused on NP. However, the rates of nail growth mean that responses to treatment will not be fully captured during typical placebo-controlled periods of ≤24 weeks. For example, in the TRANSFIGURE trial, between Week 16 (the endpoint of the placebo-controlled phase) and Week 32, nail symptoms continued to improve vs baseline: the mean percentage reduction in fingernail NAPSI was larger at Week 32 vs Week 16 by a factor of 1.4, and that of the target toenail NAPSI larger by a factor of 2.37 (ClinicalTrials.gov: NCT01807520).

Guidelines for Treatment of NP
In 2015, the Group for Research and Assessment of PsO and PsA (GRAPPA) included NP as one of the 6 key domains of PsA (peripheral arthritis, axial disease, enthesitis, dactylitis, PsO, and nail disease).77 For treatment of patients with moderate-to-severe NP, the 2015 GRAPPA treatment guidelines recommended biologic treatment with TNF, IL-12/23, and IL-17 inhibitors, choosing therapy to address as many disease domains as possible.

The recently published "Joint [American Academy of Dermatology–National Psoriasis Foundation] AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics"78 recommended biologic monotherapies for treatment of adult patients with moderate to severe plaque PsO affecting the nails (TNF inhibitors: ADA, ETN, or IFX; IL-12/23 inhibitor: ustekinumab; IL-17 inhibitors: SEC or ixekizumab).

Conclusions
NP is an important predictor of enthesitis associated with the early stages of PsA, as patients with PsO are 3 times more likely to develop PsA if they have nail symptoms. The nail sits at a fascinating nexus of the appendicular and musculoskeletal system due to the close relationship of the extensor tendon enthesis to nail structures. NP is 1 of the 6 key domains of PsA that need to be assessed to establish the prognosis and optimal treatment for individual patients.77,79 As such, it is important for rheumatologists and dermatologists to accurately diagnose and treat NP to potentially delay the onset and progression of joint disease. However, given that systemic therapies are not specifically indicated for the treatment of NP in the absence of moderate to severe skin or joint disease, there are several unmet needs in daily practice, including the lack of a simple, validated, and widely accepted NP scoring system and well-defined treatment guidelines for patients with NP without moderate or severe skin symptoms or active PsA. Further randomized studies investigating treatment of NP are needed to gather a more comprehensive pool of data. Recent imaging studies have provided important data on the anatomical link between NP and musculoskeletal...
manifestations of PsD. Expanded use of imaging modalities could be a valuable way to inform NP diagnosis and treatment decisions.

ACKNOWLEDGMENT
The authors thank Amos Race, PhD, of ArticulateScience LLC, Hamilton, NJ, USA, for providing medical writing support/editorial support, which was funded by Novartis Pharmaceuticals Corporation, East Hanover, NJ, in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3).

ONLINE SUPPLEMENT
Supplementary material accompanies the online version of this article.

REFERENCES
monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol 2017;76:405-17.

38. Mease PJ. Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composited Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res 2011;63 Suppl 11:S64-85.


